Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 411036
                    [Title] => Delaying diabetic retinopathy
                    [Summary] => The results of the FIELD (Fenofibrate Intervention and Event Lowering in Diabetes) study confirmed fenofibrate’s ...
                    [DatePublished] => 2008-10-30 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 57893
                    [Title] => Treating diabetic retinopathy
                    [Summary] => 
            
                    [DatePublished] => 2008-04-24 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [2] => Array
                (
                    [ArticleID] => 289788
                    [Title] => Managing metabolic syndrome with ‘fenofibrates’
                    [Summary] => Fenofibrate has been shown to reduce risk of coronary events, including non-fatal heart attack and stroke, in patients with metabolic syndrome. 


A study demonstrated the benefits of fenofibrate therapy in atherogenic dyslipidemia, a common risk factor for metabolic syndrome, a constellation of risk factors which also include obesity, insulin resistance and hypertension.


Atherogenic dyslipidemia is characterized by high-triglycerides, low high-density lipoprotein (HDL) and the preponderance of small low-density lipoprotein.  


                    [DatePublished] => 2005-08-04 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

FENOFIBRATE INTERVENTION AND EVENT LOWERING

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 411036
                    [Title] => Delaying diabetic retinopathy
                    [Summary] => The results of the FIELD (Fenofibrate Intervention and Event Lowering in Diabetes) study confirmed fenofibrate’s ...
                    [DatePublished] => 2008-10-30 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 57893
                    [Title] => Treating diabetic retinopathy
                    [Summary] => 
            
                    [DatePublished] => 2008-04-24 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [2] => Array
                (
                    [ArticleID] => 289788
                    [Title] => Managing metabolic syndrome with ‘fenofibrates’
                    [Summary] => Fenofibrate has been shown to reduce risk of coronary events, including non-fatal heart attack and stroke, in patients with metabolic syndrome. 


A study demonstrated the benefits of fenofibrate therapy in atherogenic dyslipidemia, a common risk factor for metabolic syndrome, a constellation of risk factors which also include obesity, insulin resistance and hypertension.


Atherogenic dyslipidemia is characterized by high-triglycerides, low high-density lipoprotein (HDL) and the preponderance of small low-density lipoprotein.  


                    [DatePublished] => 2005-08-04 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

abtest

Delaying diabetic retinopathy

October 30, 2008 - 12:00am

The results of the FIELD (Fenofibrate Intervention and Event Lowering in Diabetes) study confirmed fenofibrate’s ...

Science and Environment

Treating diabetic retinopathy

April 24, 2008 - 12:00am

Science and Environment

Managing metabolic syndrome with ‘fenofibrates’

August 4, 2005 - 12:00am

Fenofibrate has been shown to reduce risk of coronary events, including non-fatal heart attack and stroke, in patients with metabolic syndrome. A study demonstrated the benefits of fenofibrate therapy in atherogenic...

Science and Environment